Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 19/20 | 0.78 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18056644 | 0.90 | ROCK1 (0.73) | ROCK1ROCK2 | |
| SCHEMBL20023257 | 0.88 | ROCK1 (0.81) | ROCK1ROCK2 | |
| SCHEMBL18056457 | 0.88 | ROCK1 (0.80) | ROCK1ROCK2 | |
| SCHEMBL18056494 | 0.88 | ROCK1 (1.00) | ROCK1ROCK2 | |
| SCHEMBL18056270 | 0.85 | ROCK1 (0.76) | ROCK1ROCK2 | |
| SCHEMBL21349133 | 0.85 | ROCK1 (0.58) | ROCK1ROCK2 | |
| SCHEMBL18038175 | 0.84 | ROCK1 (0.66) | ROCK1ROCK2 | |
| SCHEMBL18056272 | 0.84 | ROCK1 (0.74) | ROCK1ROCK2 | |
| SCHEMBL18056501 | 0.82 | ROCK1 (0.64) | ROCK1ROCK2 | |
| Trifluoroacetic Acid SCHEMBL18038204 | 0.82 | ROCK1 (0.71) | ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-04-05 | — | — | US | disclosed |
| WO-2016138335-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | LYCERA CORPORATION (US) | 2016-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180093978-A1 | INDAZOLYL THIADIAZOLAMINES AND RELATED COMPOUNDS FOR INHIBITION OF RHO-ASSOCIATED PROTEIN KINASE AND THE TREATMENT OF DISEASE | ROCK1, ROCK2, CIT | ROCK1 1/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.